JP2020520904A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020520904A5 JP2020520904A5 JP2019563067A JP2019563067A JP2020520904A5 JP 2020520904 A5 JP2020520904 A5 JP 2020520904A5 JP 2019563067 A JP2019563067 A JP 2019563067A JP 2019563067 A JP2019563067 A JP 2019563067A JP 2020520904 A5 JP2020520904 A5 JP 2020520904A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- formula
- alkyl
- compound
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 73
- 125000000217 alkyl group Chemical group 0.000 claims 26
- 239000008194 pharmaceutical composition Substances 0.000 claims 26
- 229910052736 halogen Inorganic materials 0.000 claims 25
- 150000002367 halogens Chemical class 0.000 claims 25
- 239000000651 prodrug Substances 0.000 claims 19
- 229940002612 prodrug Drugs 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 19
- 125000000623 heterocyclic group Chemical group 0.000 claims 13
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 5
- 102000004877 Insulin Human genes 0.000 claims 4
- 108090001061 Insulin Proteins 0.000 claims 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 229940125396 insulin Drugs 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 125000003627 8 membered carbocyclic group Chemical group 0.000 claims 3
- 239000008186 active pharmaceutical agent Substances 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 230000002708 enhancing effect Effects 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 125000002837 carbocyclic group Chemical group 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000004190 glucose uptake Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 230000002438 mitochondrial effect Effects 0.000 claims 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010059245 Angiopathy Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010008616 Cholecystitis and cholelithiasis Diseases 0.000 claims 1
- 101150106966 FOXO1 gene Proteins 0.000 claims 1
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 claims 1
- 101150023900 G6PC1 gene Proteins 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 108091052347 Glucose transporter family Proteins 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 102000003746 Insulin Receptor Human genes 0.000 claims 1
- 108010001127 Insulin Receptor Proteins 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 101150029101 Pdk1 gene Proteins 0.000 claims 1
- 101150036454 Pdpk1 gene Proteins 0.000 claims 1
- 108091008611 Protein Kinase B Proteins 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 101150110386 SLC2A4 gene Proteins 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 101710107476 TBC1 domain family member 4 Proteins 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 201000001883 cholelithiasis Diseases 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 210000003674 cytoplasmic vesicle Anatomy 0.000 claims 1
- 208000001130 gallstones Diseases 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 230000009229 glucose formation Effects 0.000 claims 1
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 210000002027 skeletal muscle Anatomy 0.000 claims 1
- 210000002363 skeletal muscle cell Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762508730P | 2017-05-19 | 2017-05-19 | |
| US62/508,730 | 2017-05-19 | ||
| PCT/US2018/030371 WO2018212980A1 (en) | 2017-05-19 | 2018-05-01 | Pharmaceutical agents, compositions, and methods relating thereto |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020520904A JP2020520904A (ja) | 2020-07-16 |
| JP2020520904A5 true JP2020520904A5 (https=) | 2021-06-17 |
| JP7224303B2 JP7224303B2 (ja) | 2023-02-17 |
Family
ID=64274560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563067A Active JP7224303B2 (ja) | 2017-05-19 | 2018-05-01 | 薬剤、組成物、及びそれに関連する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11014954B2 (https=) |
| EP (1) | EP3624809A4 (https=) |
| JP (1) | JP7224303B2 (https=) |
| CN (2) | CN110545822A (https=) |
| AU (1) | AU2018269403B2 (https=) |
| CA (1) | CA3061893A1 (https=) |
| RU (1) | RU2765286C2 (https=) |
| SA (1) | SA519410561B1 (https=) |
| SG (1) | SG11201909932YA (https=) |
| WO (1) | WO2018212980A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018269403B2 (en) | 2017-05-19 | 2025-03-27 | Alltech, Inc. | Pharmaceutical agents, compositions, and methods relating thereto |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002077002A2 (en) * | 2001-03-22 | 2002-10-03 | Research Foundation Of The City University Of New York | Synthesis of selenium-derivatized nucleosides, nucleotides, phosphoramidites, triphosphates and nucleic acids |
| US20030078232A1 (en) | 2001-08-08 | 2003-04-24 | Elfatih Elzein | Adenosine receptor A3 agonists |
| EP1652519A1 (en) | 2004-10-28 | 2006-05-03 | Tamie Nasu | Seleniferous composition for producing antioxidase in vivo |
| US20060198906A1 (en) | 2005-03-07 | 2006-09-07 | Sami Labs Limited | Compositions and Method to Increase Serum Levels of HDL cholesterol and Lower the Risk of Cardiovascular Disease |
| US20070077238A1 (en) | 2005-10-04 | 2007-04-05 | Teo Alex Y | Production of organic and inorganic selenium compounds by lactic acid bacteria |
| WO2007047401A2 (en) | 2005-10-13 | 2007-04-26 | Cv Therapeutics, Inc. | A1 adenosine receptor agonists |
| WO2009032057A2 (en) | 2007-08-29 | 2009-03-12 | Adam Lubin | Method for the selective therapy of disease |
| WO2013151975A1 (en) | 2012-04-02 | 2013-10-10 | Northeastern University | Compositions and methods for the inhibition of methyltransferases |
| US9833486B2 (en) | 2013-03-15 | 2017-12-05 | Alltech, Inc. | Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction |
| RU2665135C2 (ru) * | 2014-03-14 | 2018-08-28 | Олтек, Инк. | Композиции селеноорганических соединений и способы их применения |
| US20160090397A1 (en) | 2014-09-30 | 2016-03-31 | Northeastern University | Se-Adenosyl-L-Selenohomocysteine Selenoxide As A Modulator Of Methyltransferase And Other Activities |
| WO2017048252A1 (en) * | 2015-09-15 | 2017-03-23 | Alltech, Inc. | Compositions of selenoorganic compounds and methods of use thereof |
| AU2018269403B2 (en) | 2017-05-19 | 2025-03-27 | Alltech, Inc. | Pharmaceutical agents, compositions, and methods relating thereto |
-
2018
- 2018-05-01 AU AU2018269403A patent/AU2018269403B2/en active Active
- 2018-05-01 CA CA3061893A patent/CA3061893A1/en active Pending
- 2018-05-01 SG SG11201909932Y patent/SG11201909932YA/en unknown
- 2018-05-01 RU RU2019134865A patent/RU2765286C2/ru active
- 2018-05-01 WO PCT/US2018/030371 patent/WO2018212980A1/en not_active Ceased
- 2018-05-01 CN CN201880027339.7A patent/CN110545822A/zh active Pending
- 2018-05-01 JP JP2019563067A patent/JP7224303B2/ja active Active
- 2018-05-01 CN CN202510741418.6A patent/CN120647702A/zh active Pending
- 2018-05-01 EP EP18801931.9A patent/EP3624809A4/en active Pending
- 2018-05-01 US US16/490,836 patent/US11014954B2/en active Active
-
2019
- 2019-11-14 SA SA519410561A patent/SA519410561B1/ar unknown
-
2021
- 2021-04-23 US US17/238,354 patent/US11613552B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019519598A5 (https=) | ||
| CN113365998A (zh) | 用于parp抑制剂的吲哚并七元酰肟类似物 | |
| JP2018535967A5 (https=) | ||
| JPWO2019195124A5 (https=) | ||
| JP2019531320A5 (https=) | ||
| JP2007523155A5 (https=) | ||
| KR970704435A (ko) | 헤테로시클릭 화합물의 도파민-D 리간드로서의 용도(Use of Heterocyclic Compounds as Dopamines-D Ligands) | |
| JP2019510787A5 (https=) | ||
| JP2008195730A5 (https=) | ||
| US9765031B2 (en) | Cannabinoid receptor mediating compounds | |
| JP2020502047A5 (https=) | ||
| JP2016500063A5 (https=) | ||
| EP3303325A1 (en) | Cannabinoid receptor mediating compounds | |
| US8329710B2 (en) | Metformin folate and preparation of the same | |
| JP2021519764A5 (https=) | ||
| JP2020520957A5 (https=) | ||
| JP2015508068A5 (https=) | ||
| WO2011002001A1 (ja) | ピラゾール誘導体とビグアナイド薬との組み合わせ医薬 | |
| JP2020520904A5 (https=) | ||
| CN103864699B (zh) | 具有抗HBV病毒且兼具抗HIV和HCV病毒作用的新一类非核苷S-DABOs嘧啶酮衍生物的制备和应用 | |
| CA2620065A1 (en) | Methods and formulations for modulating lyn kinase activity and treating related disorders | |
| US12195441B2 (en) | Para acyl substituted diazacyclohexene derivatives | |
| CN109836423A (zh) | 一类预防或治疗肺纤维化疾病的新化合物、制备方法及其用途 | |
| JPS5982378A (ja) | ３―アミノプロポキシフェニル誘導体およびその製法ならび用途 | |
| WO2011002011A1 (ja) | Sglt1阻害薬とdpp-iv阻害薬を組み合わせてなる医薬 |